Shorted
Immuron logo
IMC
Pharmaceuticals, Biotechnology & Life Sciences

Immuron

Short interest
0.14%
+0.12 pp 30d
as of 21 July 2025
Reported shorts
380K
Shares on issue
268.220M

Immuron (IMC) company profile

Profile, insiders and operations

Company

AI-generated research profile of Immuron

biopharmaceutical
immunotherapy
gastrointestinal health
liver disease
infectious diseases

Immuron is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapy treatments. Their proprietary technology platform utilizes dairy-derived polyclonal antibodies to address unmet medical needs in gastrointestinal health, liver diseases, and infectious diseases. Immuron's products aim to reduce diarrhea, enhance gut health, and promote immune defense.

Director trades

18 trades recorded

DateDirectorTypeSharesPriceValue
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-18Paul Brennan
other
1,000,000--
2025-11-18Daniel Pollock
other
1,000,000--
2025-11-18Ravi Savarirayan
other
1,000,000--
2025-11-18Jeannette Joughin
other
1,000,000--
2024-12-10Unknown Director
buy
---
2024-12-10Unknown Director
buy
---
2024-12-10Unknown Director
buy
---
2024-12-09Daniel Pollock
other
1,000,000--
2024-12-09Jeannette Joughin
other
1,000,000--
2024-12-09Ravi Savarirayan
other
1,000,000--
2024-11-14Unknown Director
buy
---
2024-11-13Daniel Pollock
sell
2,500,000--
2024-03-14Unknown Director
buy
---
2024-03-12Daniel Pollock
other
200,000$0.277$55,400

IMC intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required